SCHEMBL561465

SCHEMBL561465

C1=[N+]c2ncncc2N1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6987840 0.65
SCHEMBL17273531 0.64
SCHEMBL8913616 0.63
SCHEMBL3835888 0.63 HSP90AA1 (0.31)
SCHEMBL536971 0.60 LRRK2 (0.31)
SCHEMBL28151351 0.59
SCHEMBL127479 0.58 EGFR (0.50)
SCHEMBL28003243 0.56 EGFR (0.48)
SCHEMBL15386176 0.55 CDC25B (0.41)
SCHEMBL4860463 0.55

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 264 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023107490-A1 HETEROCYCLE-CONTAINING LONP1 INHIBITOR COMPOUNDS, USES AND METHODS PRETZEL THERAPEUTICS, INC. (US) 2023-06-15 WO claimed
US-11566042-B2 Phosphoramidite synthones for the synthesis of self-neutralizing oligonucleotide compounds ZATA Pharmaceuticals, Inc (US) 2023-01-31 US claimed
US-20210347645-A1 Macroporous Controlled Porosity Silica Gel Suitable For Oligonucleotide Synthesis CHEMGENES CORPORATION 2021-11-11 US claimed
EP-3906997-A2 MACROPOROUS CONTROLLED POROSITY SILICA GEL SUITABLE FOR OLIGONUCLEOTIDE SYNTHESIS Chemgenes Corporation (US) 2021-11-10 EP claimed
US-11078227-B2 5′-cyclo-phosphonate modified nucleotides Arrowhead Pharmaceuticals, Inc. (US) 2021-08-03 US claimed
US-10723755-B2 Phosphoramidite synthones for the synthesis of self-neutralizing oligonucleotide compounds ZATA PHARMACEUTICALS, INC. (US) 2020-07-28 US claimed
US-8618279-B2 Synthesis of 2′,3′— and 3′,5′—cyclic phosphate mono-and oligonucleotides CHEMGENES CORPORATION (US) 2013-12-31 US claimed
US-8153779-B2 Nucleotide with an alpha-phosphate mimetic ROCHE DIAGNOSTICS OPERATIONS, INC. (US) 2012-04-10 US claimed
US-20120034184-A1 4'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION DEVOS RENE ROBERT (GB) 2012-02-09 US claimed
JP-2007512358-A 2007-05-17 JP claimed
EP-0863757-A1 2-SUBSTITUTED ARYL PYRROLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE Merck & Co., Inc. (US) 1998-09-16 EP claimed
EP-0859771-A1 SUBSTITUTED PYRIDYL PYRROLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE Merck & Co., Inc. (US) 1998-08-26 EP claimed
WO-1997016441-A1 SUBSTITUTED ARYL PYRROLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE MERCK & CO., INC. (US) 1997-05-09 WO claimed
WO-1997016442-A1 SUBSTITUTED PYRIDYL PYRROLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE MERCK & CO., INC. (US) 1997-05-09 WO claimed
WO-1997016426-A1 SUBSTITUTED ARYL PYRROLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE MERCK & CO., INC. (US) 1997-05-09 WO claimed
WO-1997005878-A1 2,5-SUBSTITUTED ARYL PYRROLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE MERCK & CO., INC. (US) 1997-02-20 WO claimed
WO-1997005877-A1 2-SUBSTITUTED ARYL PYRROLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE MERCK & CO., INC. (US) 1997-02-20 WO claimed
EP-0719274-A1 METHOD FOR DOSING THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. (US) 1996-07-03 EP claimed
WO-1995007919-A1 METHOD FOR DOSING THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. (US) 1995-03-23 WO claimed
EP-0340778-A2 Prodrugs of 2',3'- Didehydro-2',3'-Dideoxynucleosides Bristol-Myers Squibb Company (US) 1989-11-08 EP claimed